Brind.
  1. The FDA is reviewing applications for new medical treatments, including a C5 complement inhibitor for IgAN.

The FDA granted accelerated approval for the drug TRUTAKNA for use in patients with IgAN.

1 report, 1 independent Updated Aug 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The FDA granted accelerated approval for the drug TRUTAKNA for use in patients with IgAN.

Who's involved

What this event is mainly about
FDA

Keep exploring

Part of

The FDA is reviewing applications for new medical treatments, including a C5 complement inhibitor for IgAN.

Also in this story

All 3 developments

The entities involved

Coverage

Newest first; wire copies grouped